U
Umesh G. Lalloo
Researcher at University of KwaZulu-Natal
Publications - 136
Citations - 9744
Umesh G. Lalloo is an academic researcher from University of KwaZulu-Natal. The author has contributed to research in topics: Tuberculosis & Population. The author has an hindex of 39, co-authored 129 publications receiving 9015 citations. Previous affiliations of Umesh G. Lalloo include University of Natal & Imperial College London.
Papers
More filters
Journal ArticleDOI
Transmissible cancer in Africa – Authors' reply
Bongani M. Mayosi,Bongani M. Mayosi,Alan J. Flisher,Alan J. Flisher,Umesh G. Lalloo,Freddy Sitas,Stephen Tollman,Stephen Tollman,Debbie Bradshaw +8 more
Journal ArticleDOI
Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trial
Mariana Araújo-Pereira,Sonya Krishnan,Padmini Salgame,Yukari Manabe,Mina C. Hosseinipour,Gregory P. Bisson,Damocles Patrice Severe,Vanessa Rouzier,Samantha Antonio Leong,Vidya Mave,Fred Sawe,Abraham Siika,Cecilia Kanyama,Sufia Dadabhai,Javier R. Lama,Javier Valencia-Huamaní,Sharlaa Badal-Faesen,Umesh G. Lalloo,Kogieleum Naidoo,Lerato Mohapi,Cissy Kityo,Bruno B. Andrade,Amita Gupta +22 more
TL;DR: In this paper , the authors performed multidimensional analyses, logistic regression analyses, survival curves, and Bayesian network analyses to delineate associations between anaemia, laboratory parameters, and clinical outcomes.
Journal ArticleDOI
Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349).
April C. Pettit,Patrick P. J. Phillips,Ekaterina V. Kurbatova,Andrew Vernon,Payam Nahid,Rodney Dawson,Kelly E. Dooley,Ian Sanne,Z. Waja,Lerato Mohapi,Anthony T. Podany,Wadzanai Samaneka,Rada M. Savic,John E. Johnson,Grace Muzanyi,Umesh G. Lalloo,Kia E Bryant,Erin Sizemore,Nigel A. Scott,Susan E. Dorman,Richard E. Chaisson,Susan Swindells +21 more
TL;DR: In people with HIV-associated DS-PTB with CD4 + counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was non-inferior to the 6-month control regimen and was safe.
Journal ArticleDOI
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group
Umesh G. Lalloo,Lauren Komarow,Judith A. Aberg,David B. Clifford,Evelyn Hogg,Ashley McKhann,Aggrey Bukuru,David Lagat,Sandy Pillay,Vidya Mave,Khuanchai Supparatpinyo,Wadzanai Samaneka,Deborah Langat,Eduardo Ticona,Sharlaa Badal-Faesen,Robert A. Larsen +15 more
TL;DR: A 2-stage AMB-controlled, dose-escalation study to determine the maximum tolerated dose and the safety/efficacy of an induction-consolidation strategy of higher doses of fluconazole (1200mg-2000mg/day), adjusted for weight and renal function (eGFR) in adults with cryptococcal meningitis (CM) was undertaken as discussed by the authors .
Journal ArticleDOI
One-year incidence of tuberculosis infection and disease among household contacts of rifampin- and multi-drug resistant tuberculosis.
Sonya Krishnan,Xingye Wu,Soyeon Kim,Katherine N. McIntire,Linda Naini,Michael Hughes,Rodney Dawson,Vidya Mave,Sanjay Gaikwad,Jorge Torres Sánchez,Alberto Mendoza-Ticona,Pedro Gonzales,Kyla Comins,Justin Shenje,Sandy Nerette Fontain,A. Omozoarhe,Lerato Mohapi,Umesh G. Lalloo,A. C.Garcia Ferreira,Christopher Mugah,M. Harrington,N. Sarita Shah,Anneke C. Hesseling,Gavin J. Churchyard,Susan Swindells,Amita Gupta +25 more
TL;DR: In this article , the authors conducted a cross-sectional study of HHCs of rifampin/multidrug-resistant tuberculosis in 8 high-burden countries and re-assessed TBI (interferon-gamma release assay, HHC ≥5 years) and TBD (HHCs all ages) at one-year.